Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial
Heikki Joensuu(Orion Corporation (Finland)), Henrik Lindman(Uppsala University), R. Kokko, Paula Poikonen‐Saksela(Turku University Hospital), Arja Jukkola‐Vuorinen(University of Oulu), Päivi Auvinen(University of Eastern Finland), Minna Tanner(Tampere University Hospital), Paul Nyandoto(Päijät-Hämeen Keskussairaala), Johan Ahlgren(Uppsala University), Vesa Kataja(Kuopio University Hospital), Outi Paija(Turku University Hospital), Riikka Huovinen(Turku University Hospital), R. Asola(Satakunta Central Hospital), Marjo Pajunen(Central Finland Health Care District), Greger Nilsson(Turku University Hospital), Pirkko‐Liisa Kellokumpu‐Lehtinen, Kenneth Villman(Örebro University Hospital), Petri Bono(Helsinki University Hospital), Mika Leinonen, Leena Helle(Kotka Maritime Research Centre)
Cited by 118
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
|New England Journal of Medicine|2006|1.4k